Extracorporeal Membrane Oxygenation Machine Market Size Report, 2022-2030
The global Extracorporeal Membrane Oxygenation Machine market size was estimated at USD 539 Million in 2021 and is expected to surpass around USD 710 Million by 2030 and poised to grow at a compound annual growth rate (CAGR) of 6.9% during the forecast period 2022 to 2030.
The major factors driving the growth of this market include the increasing geriatric population and growth in disease incidence as well as favorable government regulations, investments, and initiatives. The advantages of ECMO machines have played a key part in their adoption; their speed and accuracy, as well as quick processing times, allow for significantly higher patient screening volumes than earlier. This has pushed companies to focus on product development and innovation. However, these systems are priced at a premium, which slows their greater adoption. Other factors such as declining reimbursements, lack of infrastructure, particularly in developing and underdeveloped countries, and potential risks associated with radiation exposure are also expected to hinder the growth of this market.
Report Scope of the Extracorporeal Membrane Oxygenation Machine Market
|
Report Coverage |
Details |
|
Market Size |
US$ 710 Million by 2030 |
|
Growth Rate |
CAGR of 6.9% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Patient Type, Application, Modality Outlook, Product, Component and Region, |
|
Companies Mentioned |
Getinge Group (Sweden), Medtronic plc (US), Fresenius Medicalcare AG & Co. KGAA (Germany), Microport (China), and Terumo Cardiovascular Systems Corporation (Japan). Livanova plc (UK), Nipro Corporation (Japan), Eurosets S.R.L. (Italy), Origin Biomedical (US), Cytosorbents Corporation (Australia), and Abiomed (US). |
COVID-19 Impact on the global ECMO machine market
The COVID-19 pandemic adversely affected the economy in 2020 and presented various challenges to clinical healthcare providers and patients across the globe. COVID-19 has also impacted various stages of the value chain, primarily due to strict lockdowns imposed by the governments of most countries. The turnaround time for the delivery of products and services has also been affected due to newer packaging protocols and lockdown measures imposed by countries. All these factors are negatively impacting the manufacturing and supply chain of digital X-ray systems.
However, COVID-19 has unleashed new opportunities for ECMO machine manufacturers and healthcare providers. In settings where laboratory testing (RT-PCR) is not available, or results are delayed or are initially negative, chest imaging has been considered as an alternative approach for patients with suspected or probable COVID-19. Imaging, including chest radiography, CT scans, and lung ultrasounds, has been considered to complement clinical evaluation and laboratory parameters in managing patients already diagnosed with COVID-19. According to the WHO, chest radiography can be helpful in the dynamic evaluation of COVID-19 pneumonia and its complications. Resolution or the progress of lung consolidation seen on a bedside chest radiograph can help caregivers make better therapeutic management decisions. Chest imaging can also inform the management of pneumothorax or pneumomediastinum.
ECMO Machine Market Dynamics
Driver: Growing adoption of ECMO in Lung Transplantation Prrocedures
The number of lung transplantation has increased in the last few decades, especially in the treatment of end stage lung diseases such as Chronic Obstructive Pulmonary Disease (COPD), Interstitial Lung Disease and Cystic Fibrosis.
Over the years, the adoption of ECMO machine in lung transplantation procedure has increased significantly in the management of patients with severe lung disease. The most common indication for the use of ECMO is Primary Graft Dysfunction (PGD) post lung transplantation. PGD is a syndrome consisting of lung injusry during the first 72 hours following lung transplant. With significant improvements in technologies, several studies have shown positive outcomes related to the use of ECMO as a bridging strategy as well as therapy for patients suffering from PGD, post-transplant.
With the increasing prevalence of lung diseases across the globe, the use of ECMO is expected to rise further in the coming years.
Restraint: High cost of ECMO products
ECMO is an expensive therapy. Apart from the costs associated with the systems, other expenses include cost of staying at the hospital and the cost of additional disposable accessories. In addition to this, an entire team of medical professionals is required to take care of the patient undergoing an ECMO procedure, which adds to the cost of the treatment, although it differs depending upon the duration of its use. The average hospital stay for a patient with ECMO support is typicaly 1-2 weeks, however, it varies on the severity of the illness and can extend beyond this time frame. This increases the overall expense of the procedure which most patients can’t afford.
Opportunity: Increasing survival rates with ECMO
Survival rates of ECMO patients vary depending on the underlying condition and the patient’s age. VV-ECMO is indicated for patients with potentially reversible respiratory failure, including those with severe acute respiratory distress syndrome (ADRS), primary graft dysfunction post a lung transplant, and trauma to the lungs. Using VV-ECMO for respiratory failure patients increase their survival rates.
ECMO machines are also used for cardiac applications due to its ability to support failing cardiovascular systems with oxygenation functions. Using these systems for cardiac failures improve the survival rates for cardiac patients. Improving the survival rates with ECMO is expected to provide favourable growth opportunities for the ECMO market.
Challenge: Lack of Skilled Professionals
Lack of skilled professionals is one of the major challenges in the ECMO market. Despite the health sector employing millions of workers across the globe it continues to have low density health professionals according to a World Health Organization database.
Respiratory segment accounted for the largest share of global ECMO machine market in 2020
On the basis of applications, the ECMO machine market is segmented into respiratory, cardiac and ECPR applications. The respiratory segment is expected to dominate this market during the forecast period. Growth in this market can be attributed to the increasing prevalence of target diseases, high demand for early diagnosis and diagnostic imaging, and technological advancements in the ECMO machine market. Moreover, the rising prevalence of lung diseases like tuberculosis, thoracic malignancies, osteoporosis, fractures, and CVDs increases the demand for medical imaging for diagnosis.
Arterio-Venous segment accounted for the largest market share of the ECMO machine market in 2020
On the basis of modality, the ECMO machine market is segmented into veno-arterio, veno-venous and arterio-venous. The arterio-venous segment accounted for the larger market share. The advantages associated with this segment, such as effective dynamic range, better medical evaluation, are contributing to the growth of this technology segment.
Increasing number of disorders/diseases in growing population resulting in an increase in the purchase of ECMO machines
On the basis of patient type, the ECMO machine market is segmented into neonates, pediatric and adults. The adult segment contributed to the largest share of global ECMO machine market in 2020. ECMO has been used for more than 40 years, and its benefits with neonates with respiratory distress are well recognized. The benefits of ECMO in adult patients with cardiac or respiratory failure are still debated, as ECMO was initially associated with low survival rates. However, recent technological advancements in ECMO circuits have led to a reduction in the rate of technical issues and complications.
Controllers, by component, have contributed the largest share in the ECMO machine market
Based on component, the global ECMO machine market is segmented into pumps, oxygenators, controllers, cannula and accessories. The controllers segment is expected to dominate the market during the forecast period. The large share of this segment can be attributed to the greater adoption of the systems among end users due to their lowercost compared to others.
Portable ECMO machine Segment, by product type, has commanded the highest growth rate in the forecast period
Based on product type, the ECMO machine market is segmented into Static ECMO machines and Portable ECMO machines. Portable ECMO machine segment is expected to dominate the market during the forecast period. Portable ECMO machines can be transported to any desired location and they are light in weight. These systems are especially used in a variety of imaging-set ups, including intensive care units, cardiac care units, neonatal intensive care units, operating rooms, emergency rooms, and at the patient’s beside for critically ill patients or patients with mobility challenges.
The APAC market, by region, to register highest growth rate in the forecast period
The ECMO Machine market is segmented into five major regions—North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The asia-pacific market is expected to register the highest growth in the forecast period. Growth in the ECMO machine market in the Asia Pacific is mainly driven by the growing geriatric population, particularly in Japan; increasing disposable incomes, allowing for greater affordability for advanced technologies; the rising prevalence of target diseases; and favorable government initiatives. Such factors help to drive the market for digital imaging systems in this region and draw foreign investments and partnerships. On the other hand, low hospital budgets, high equipment costs, and a lack of government investments in some countries are limiting the growth of the market in the Asia Pacific to a certain extent.
Some of the prominent players in the Extracorporeal Membrane Oxygenation Machine Market include: Getinge Group (Sweden), Medtronic plc (US), Fresenius Medicalcare AG & Co. KGAA (Germany), Microport (China), and Terumo Cardiovascular Systems Corporation (Japan). The other leading market players include Livanova plc (UK), Nipro Corporation (Japan), Eurosets S.R.L. (Italy), Origin Biomedical (US), Cytosorbents Corporation (Australia), and Abiomed (US).
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Extracorporeal Membrane Oxygenation Machine market
Global ECMO machine market, by Product
Global ECMO machine market, by Component
Global ECMO machine market, by Modality Outlook
Global ECMO machine market, by Portability
Global ECMO machine market, by Patient Type
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Extracorporeal Membrane Oxygenation Machine Market Study:
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers